Icon (ICLR) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$8.3B

Revenue (quarter)

$2.1B

Revenue growth (year over year)

+1.20%

Gross profit (trailing twelve months)

$234.9M

Gross margin

2.83%

Net income (trailing twelve months)

$27.0M

Net income (quarter)

$72.6M

Net income growth (year over year)

−64.34%

Net margin

0.33%

Return on equity

0.29%

EPS (trailing twelve months)

$0.48

Book value per share

$121.55

P/E (trailing twelve months)

480.73

Price to book

1.39

Debt to assets

42.82%

Payout ratio

—

Dividend yield

—

Company profile

Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.

• Is Icon (ICLR) profitable?

  Yes. Icon earned $27.0M in net income over the trailing twelve months, a net margin of 0.33%.

• How much revenue does Icon (ICLR) make?

  Icon generated $8.3B in revenue over the trailing twelve months, up 1.20% year over year.

• What is ICLR's P/E ratio?

  Icon trades at 480.7 times trailing twelve-month earnings, on an EPS of $0.48.

• How do I buy stock in Icon (ICLR)?

  ICLR trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.